Matinas BioPharma Statistics
Matinas BioPharma (6LJ) Stock Statistics & Valuation Metrics
Total Valuation
Matinas BioPharma has a market cap or net worth of EUR 866.66K. The enterprise value is EUR 1.94M.
- Market Cap
- EUR 866.66K
- Enterprise Value
- EUR 1.94M
Share Statistics
Matinas BioPharma has 1,113,528 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,113,528
- Owned by Insiders
- 8.38%
- Owned by Institutions
- 0.85%
Financial Efficiency
Matinas BioPharma’s return on equity (ROE) is -2.14 and return on invested capital (ROIC) is -108.06%.
- Return on Equity (ROE)
- -2.14
- Return on Assets (ROA)
- -1.44
- Return on Invested Capital (ROIC)
- -108.06%
- Return on Capital Employed (ROCE)
- -1.21
- Revenue Per Employee
- 0
- Profits Per Employee
- -5.17M
- Employee Count
- 2
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Matinas BioPharma is -0.05. Matinas BioPharma’s PEG ratio is -0.00.
- PE Ratio
- -0.05
- PS Ratio
- 0.00
- PB Ratio
- 0.21
- Price to FCF
- -0.06
- Price to Operating Cash Flow
- -0.06
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Matinas BioPharma had revenue of 0 and earned -10.35M in profits. Earnings per share was -30.00.
- Revenue
- 0
- Gross Profit
- -456.00K
- Operating Income
- -6.96M
- Pretax Income
- -10.35M
- Net Income
- -10.35M
- EBITDA
- -9.89M
- Earnings Per Share (EPS)
- -30.00
Cash Flow
In the last 12 months, operating cash flow was -6.42M and capital expenditures 0, giving a free cash flow of -6.42M billion.
- Operating Cash Flow
- -6.42M
- Free Cash Flow
- -6.42M
- Free Cash Flow per Share
- -15.03
Dividends & Yields
Matinas BioPharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1845.14%
- Earnings Yield
- -2100.64%
Stock Price Statistics
- Beta
- ―
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 0.05
- 200-Day Moving Average
- 0.05
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Matinas BioPharma upcoming earnings date is ―, TBA (Confirmed).
- Last Earnings Date
- May 07, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Matinas BioPharma as a current ratio of 2.79, with Debt / Equity ratio of 28.03%
- Current Ratio
- 2.79
- Quick Ratio
- 2.79
- Debt to Market Cap
- 0.22
- Net Debt to EBITDA
- 0.27
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Matinas BioPharma has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Matinas BioPharma EV to EBITDA ratio is 0.06, with an EV/FCF ratio of 0.06.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.06
- EV to Free Cash Flow
- 0.06
- EV to Operating Cash Flow
- 0.06
Balance Sheet
Matinas BioPharma has EUR 761.00K in cash and marketable securities with EUR 6,000.00 in debt, giving a net cash position of EUR 755.00K billion.
- Cash & Marketable Securities
- EUR 761.00K
- Total Debt
- EUR 6,000.00
- Net Cash
- EUR 755.00K
- Net Cash Per Share
- EUR 0.68
- Tangible Book Value Per Share
- -EUR 1.08
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%

